ATC Group: N06AG02 Moclobemide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06AG02 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06A Antidepressants
4 N06AG Monoamine oxidase A inhibitors
5 N06AG02 Moclobemide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.3 g

Active ingredients in N06AG02

Active Ingredient Description
Moclobemide

Moclobemide is an antidepressant which affects the monoaminergic cerebral neurotransmitter system by means of a reversible inhibition of monoamine oxidase preferentially of type A (RIMA).

Related product monographs

Title Information Source Document Type  
MANERIX Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Canada (CA)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.